Preclinical studies in rodent models of cerebral ischemia–reperfusion injury have demonstrated that Edaravone Dexborneol reduces infarct volume, alleviates cerebral edema, and downregulates proinflammatory mediators such as IL-1β and MMP9 (26). The gene discussed is IL1B; the disease is Cerebral ischemia.